Business
Half-year Report
4basebio PLC reported revenues of £1.2 million for the first half of 2025, a 25% increase compared to the full year 2024. The company holds cash balances of £26.1 million at the period's end. However, the company experienced a loss for the period of £7.8 million, which is greater than the £5.7 million loss in H1 2024, due to strategic investments. Net cash outflow from operating activities was £8.2 million, compared to £5.1 million in the first half of the previous year. The company's non-current assets increased to £8.2 million, while current assets decreased to £28.7 million. Share capital increased by £16k following share issuance under employee incentive plans. Disclaimer*
About this update from 4basebio Plc
[{"type":"text","content":"\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Press Release \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n 4basebio PLC\n \n \n (\"4basebio\", the \"Company\" or the “Group”)\n \n \n \n \n \n \n \n \n \n \n \n \n \n Half-year Reportfor the six months ended 30 June 2025\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Cambridge, UK, 29 September 2025\n \n – 4basebio PLC\n (AIM: 4BB),\n an innovation\n -led provider\n of \n novel\n synthetic DNA products and \n a \n non-viral, thermostable nucleic acid delivery platform, announces its unaudited half-year results for the six months ended 30 June 2025.\n \n \n \n \n \n \n \n \n \n \n \n \n Operational Highlights (including post period end) \n \n \n \n \n \n \n \n \n \n \n \n \n \n Receipt of MHRA GMP manufacturing \n licence\n for the \n Group’s\n UK facility, enabling the supply of both Investigational Medicinal Product Drug Substance and Critical Starting Biological Materials.\n \n \n \n \n \n \n \n \n \n \n \n \n Expansion of intellectual property portfolio to 31 patent families, reinforcing 4basebio’s leading position in synthetic DNA.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Financial Highlights\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Revenues for the half year of £1.2 million, 25% higher than full year 2024\n \n \n \n \n \n \n \n \n \n \n \n \n Cash balances of £26.1 million at period end following the equity increase in 2024 \n \n \n \n \n \n \n \n \n \n \n \n \n Loss for the period of £7.8 million (H1 2024 loss: £5.7 million) due to continued strategic investments in technology, manufacturing and commercial capability\n \n \n \n \n \n \n \n \n \n \n \n \n Net cash outflow from operating activities of £8.2 million (H1 2024: £5.1 million)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Commenting on the interim results, Dr Heikki Lanckriet, CEO and CSO, said \n \n \n “We are very pleased with the progress in the first half of the year in particular \n \n \n in relation to\n \n \n revenue growth and MHRA regulatory approval. The half year also saw an important client ...